Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

Phase 2

Completed

Conditions: Hyperuricemia
Gout

Interventions: Drug: Placebo comparator
Drug: Arhalofenate
Drug: Colchicine

Registration Number: NCT01336686

Lead Sponsor: CymaBay Therapeutics, Inc.

Brief Summary: The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 67

Inclusion Criteria

Read and sign the informed consent after the elements of consent have been fully explained and all questions have been addressed, prior to any study procedures.
Known gout patient (per criteria of the American Rheumatism Association for the classification of the acute arthritis of primary gout in Appendix 3)
- the sUA must be ≥ 8.0 mg/dL and ≤12 mg/dL
- if on ULT, the patients must agree to temporarily discontinue their existing ULT and the sUA must be ≥ 8.0 mg/dL and ≤12 mg/dL after wash-out at Week -1
Male or female, 18-75 years of age at Screening Visit
All female patients must be surgically sterile or post-menopausal (at least 45 years of age with no history of menses for at least 2 years; or any age with no history of menses for at least 6 months and serum FSH ≥ 40 mIU/mL) or have a partner who has undergone vasectomy or must agree to use two medically accepted methods of contraception including a barrier method (see the list in Appendix 4) for the entire duration of the study unless reporting complete sexual abstinence.
Female patients must not be pregnant or lactating
Male patients with a female partner of child-bearing potential must agree to use condom or the partner must use a medically acceptable method of contraception for the entire duration of the study.
Patients must have an estimated CrCl ≥ 60 mL/min as calculated by the Cockcroft-Gault method
Serum creatinine value must be ≤ 1.1 mg/dL in females and ≤ 1.3 mg/dL in males
Patients must have liver function tests ≤ 1.5X ULN for AST, ALT and T-bilirubin, ≤ 2X ULN for ALP, ≤ 3X ULN for GGT; and ≤ 3X ULN for CK
All other clinical laboratory parameters must be within normal limits or considered not clinically significant for participation in this study
Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically significant for participation in this study
Patients must have a systolic blood pressure ≤ 160 mm Hg and a diastolic blood pressure ≤ 90 mm Hg; known hypertensive patients controlled with medication other than thiazide diuretics (BP reading as above) may be included

Exclusion Criteria

Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder, or organ transplant).
Known patient with xanthinuria
History of documented or suspected kidney stones
Over producers of uric acid as evidenced by 24-hour urinary uric acid > 800 mg (on normal unrestricted diet)
Known infection with the human immunodeficiency virus (HIV) or history of viral hepatitis type B or C
History of illicit drug or alcohol abuse within last 1 year
History of significant pulmonary disease, upper GI bleeding, documented peptic ulcer disease (unless known H. pylori infection treated successfully without recurrence), or nephrotic syndrome within last 3 years
All patients must not have had a stroke, TIA, acute myocardial infarction, congestive heart failure (NYHA Class II-IV), angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization), lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy within last 5 years
Malignancy within the last 5 years (except resected basal cell carcinoma)
Body mass index (BMI) > 42 kg/m2
Current or expected requirement for anticoagulant therapy (except for ≤ 325 mg/day aspirin and/or Plavix® 75 mg/day)
Rheumatoid arthritis or other autoimmune disease requiring ongoing treatment
Current or expected treatment with potent CYP3A4 inhibitors (See in Appendix 6), ranolazine, digoxin, cyclosporine, cyclophosphamide and other cytotoxic agents, sulphonylurea, thiazolidinedione, diuretic, atypical antipsychotic agents, and phenytoin
Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs use to treat acute flares are permitted)
Current or expected treatment with systemic corticosteroids (except topical, ophthalmic, intra-articular, or inhaled at a dose < 1600 μg/day) other than to treat acute flares
Known hypersensitivity to colchicine
Treatment with any other investigational therapy within the 30 days prior to the Screening Visit, or patients who received at least one dose of blinded study drug while enrolled in any previous MBX-102 trial
Any other condition that compromises the ability of the patient to provide informed consent or to comply with the objectives and procedures of this protocol, as judged by the investigator and/or medical monitor

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arhalofenate 400 mg	Colchicine	-
Arhalofenate 600 mg	Colchicine	-
Placebo	Placebo comparator	-
Placebo	Colchicine	-
Arhalofenate 400 mg	Arhalofenate	-
Arhalofenate 600 mg	Arhalofenate	-